Figure 1
Adjusted least squares mean (LSM) change in HbA1c (A), mean urine glucose/creatinine ratio (B), adjusted LSM change in FPG (C), adjusted LSM change in 2-h PPG (D), adjusted LSM change in body weight (E), adjusted LSM change in SBP (F), and mean eGFR (G) over 104 weeks of treatment. Error bars show 95% CIs. *P < 0.05, **P < 0.01, ***P < 0.001 vs. exenatide QW plus dapagliflozin (P values at weeks 52 and 104 are nominal).

Adjusted least squares mean (LSM) change in HbA1c (A), mean urine glucose/creatinine ratio (B), adjusted LSM change in FPG (C), adjusted LSM change in 2-h PPG (D), adjusted LSM change in body weight (E), adjusted LSM change in SBP (F), and mean eGFR (G) over 104 weeks of treatment. Error bars show 95% CIs. *P < 0.05, **P < 0.01, ***P < 0.001 vs. exenatide QW plus dapagliflozin (P values at weeks 52 and 104 are nominal).

Close Modal

or Create an Account

Close Modal
Close Modal